Lipophilicity and cardiovascular outcome in patients with CHF.
Ford
John S
JS
Tayek
John A
JA
D000368:Aged; D000069059:Atorvastatin; D005464:Fluorobenzenes / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006538:Heptanoic Acids / Q000737:chemistry; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D008055:Lipids / Q000737:chemistry; D008148:Lovastatin / Q000737:chemistry; D017035:Pravastatin / Q000737:chemistry / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000737:chemistry; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use
D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D008148:Lovastatin; D000069059:Atorvastatin; D017035:Pravastatin